VectorBuilder, a global leader in gene delivery technologies and CDMO solutions, today announced MuteFree™ AAV, a ...
New expedited service line designed for biotechs with timeline constraints, launched in response to client demandCan accelerate timeline to GMP ...
Andelyn Biosciences, a leading and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), announced today a partnership with Evolyra Therapeutics to ...
Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company developing next-generation cardiovascular therapeutics, and its clinical development division Sardocor, today announced that the U.S.
Adeno-associated viruses (AAVs) are as small, replication-defective, non-enveloped viruses, serving as vectors for gene therapy. AAV vectors play a transformative role in delivering therapeutic genes ...
The "Adeno-Associated Viral (AAV) Vector Market Industry Trends and Global Forecasts to 2035: Distribution by Type of Therapy, Therapeutic Area, Route of Administration, Scale of Operation and ...
The first vector-delivered gene therapies to receive FDA approval for clinical use were Luxturna,1 Spark Therapeutics’ vision loss cure, and Zolgensma,2 Novartis’ spinal muscular atrophy treatment.
Morning Overview on MSN
Compact CRISPR tool boosts in-body gene editing to 90% in lab tests
For the millions of people living with genetic diseases like muscular dystrophy and inherited liver disorders, one of the ...
The viral vector specialist SIRION Biotech has announced the signing of a preferred partnership agreement with Heidelberg University Hospital ...
VectorBuilder, a global leader in gene delivery technologies and CDMO solutions, today announced MuteFree AAV, a high-stability AAV vector designed to address ITR instability, a common challenge in ge ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results